EGFR and neoplasm: The results of this study suggest that tumor-targeted nanobioconjugate carrying EGFR AON with significant anti-tumor activity against EGFR-positive TNBC may represent a new generation of cancer therapeutics with a potential for efficacy against triple negative breast cancers.